CN118076605A - 经取代的1H-吡唑并[4,3-c]喹啉、制备方法及其用途 - Google Patents

经取代的1H-吡唑并[4,3-c]喹啉、制备方法及其用途 Download PDF

Info

Publication number
CN118076605A
CN118076605A CN202280067758.XA CN202280067758A CN118076605A CN 118076605 A CN118076605 A CN 118076605A CN 202280067758 A CN202280067758 A CN 202280067758A CN 118076605 A CN118076605 A CN 118076605A
Authority
CN
China
Prior art keywords
alkyl
pyrazolo
methoxy
quinolin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280067758.XA
Other languages
English (en)
Chinese (zh)
Inventor
鲁本·阿巴扬
奥列格·米特金
弗拉迪斯拉夫·泽诺诺维奇·帕钦斯基
阿列克谢·普什尼科夫
亚历山大·瓦西里耶维奇·伊瓦奇琴科
尼古拉·萨楚克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lomone Therapy Co
Original Assignee
Lomone Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lomone Therapy Co filed Critical Lomone Therapy Co
Publication of CN118076605A publication Critical patent/CN118076605A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280067758.XA 2021-10-15 2022-10-03 经取代的1H-吡唑并[4,3-c]喹啉、制备方法及其用途 Pending CN118076605A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256260P 2021-10-15 2021-10-15
US63/256,260 2021-10-15
PCT/US2022/045555 WO2023064133A1 (en) 2021-10-15 2022-10-03 SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF

Publications (1)

Publication Number Publication Date
CN118076605A true CN118076605A (zh) 2024-05-24

Family

ID=85988576

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280067758.XA Pending CN118076605A (zh) 2021-10-15 2022-10-03 经取代的1H-吡唑并[4,3-c]喹啉、制备方法及其用途

Country Status (11)

Country Link
US (1) US20250011319A1 (https=)
EP (1) EP4416146A4 (https=)
JP (1) JP2024539633A (https=)
KR (1) KR20240093606A (https=)
CN (1) CN118076605A (https=)
AU (1) AU2022364646B2 (https=)
CA (1) CA3233233A1 (https=)
MX (1) MX2024004569A (https=)
TW (2) TWI863003B (https=)
WO (1) WO2023064133A1 (https=)
ZA (1) ZA202406375B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118666857A (zh) * 2024-06-26 2024-09-20 江西农业大学 一种喹啉类化合物及其在农用杀菌剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080729A2 (en) * 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
MA42456B1 (fr) * 2015-06-25 2021-06-30 Univ Health Network Inhibiteurs de hpk1 et leurs procédés d'utilisation
US12486264B2 (en) * 2019-03-26 2025-12-02 Janssen Pharmaceutica Nv Bicyclic HPK1 inhibitors
US20210269434A1 (en) * 2020-01-10 2021-09-02 Incyte Corporation Tricyclic compounds as inhibitors of kras
AU2021254794A1 (en) * 2020-04-16 2022-12-15 Incyte Corporation Fused tricyclic KRAS inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118666857A (zh) * 2024-06-26 2024-09-20 江西农业大学 一种喹啉类化合物及其在农用杀菌剂中的应用
CN118666857B (zh) * 2024-06-26 2025-02-25 江西农业大学 一种喹啉类化合物及其在农用杀菌剂中的应用

Also Published As

Publication number Publication date
AU2022364646B2 (en) 2025-10-09
EP4416146A1 (en) 2024-08-21
ZA202406375B (en) 2025-01-29
CA3233233A1 (en) 2023-04-20
AU2022364646A1 (en) 2024-03-28
JP2024539633A (ja) 2024-10-29
TW202317567A (zh) 2023-05-01
TWI863003B (zh) 2024-11-21
TW202442645A (zh) 2024-11-01
MX2024004569A (es) 2024-04-30
US20250011319A1 (en) 2025-01-09
WO2023064133A1 (en) 2023-04-20
EP4416146A4 (en) 2025-11-05
KR20240093606A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
KR102815634B1 (ko) 면역조절제로서 복소환형 화합물
JP6775645B2 (ja) Ｐｉｍキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物
CN108473495B (zh) 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
WO2022247760A1 (zh) 作为kras抑制剂的杂环化合物，及其制备和治疗用途
CA2821712C (en) Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors
EP2763533B1 (en) Triazolyl pde10 inhibitors
TW201835067A (zh) 作為ｍａｌｔ１抑制劑之吡唑衍生物
AU2017376629A1 (en) Benzimidazole compounds as c-Kit inhibitors
JP2010522765A (ja) 受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物
KR20030070050A (ko) 헤테로시클릭 에테르 치환 이미다조퀴놀린
WO2008018426A1 (en) Pyrimidine derivative as pi3k inhibitor and use thereof
CN103282363B (zh) 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
KR20180052702A (ko) Perk 억제제로서의 1-페닐피롤리딘-2-온 유도체
JP2021527654A (ja) Ｍａｌｔ１阻害剤としてのピラゾール誘導体
KR20170075756A (ko) 카르바졸 유도체
CA3186348A1 (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
TW202340181A (zh) 雜環化合物及其用途
TW202339721A (zh) Bcl-xL抑制劑
CN114981256B (zh) 干扰素基因刺激物sting的单环激动剂
TWI863003B (zh) 經取代的 1H-吡唑并[4,3-c]喹啉、製備方法及其用途
CN113891880A (zh) 作为吲哚胺2,3-双加氧酶的选择性抑制剂的酰胺取代的咪唑并化合物
CN116981458A (zh) 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物
JP2023539526A (ja) インターフェロン遺伝子刺激因子ｓｔｉｎｇのアゴニスト
CN115003383B (zh) 干扰素基因刺激物sting的双环激动剂
HK40081945A (en) Bicyclic agonists of stimulator of interferon genes sting

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination